Prescribe an SGLT2 inhibitor for heart failure in the absence of diabetes?

被引：2
|
作者：
Koenigsberger, Debra [1 ]
Marquez, Alexander [1 ]
Hughes, Pamela R. [1 ]
Mullen, Rebecca [2 ]
机构：
[1] Nellis AFB Family Med Residency, Las Vegas, NV USA
[2] Univ Colorado, Dept Family Med, Denver, CO 80202 USA
来源：
JOURNAL OF FAMILY PRACTICE | 2021年 / 70卷 / 06期
关键词：
RISK;
D O I：
10.12788/jfp.0235
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
[No abstract available]
引用
收藏
页码：E7 / E9
页数：3
相关论文
共 50 条
  • [1] SGLT2 inhibitor dapagliflozin lowers risk of heart failure in diabetes
    Overbeck P.
    MMW - Fortschritte der Medizin, 2018, 160 (20) : 18 - 19
  • [2] SGLT2 inhibitor-related AEs differ with heart failure and diabetes
    Reactions Weekly, 2024, 2031 (1) : 11 - 11
  • [3] SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure
    Verma, Ashish
    Patel, Ankit B.
    Waikar, Sushrut S.
    CELL METABOLISM, 2020, 32 (01) : 13 - 14
  • [4] SGLT2 Inhibitor Use in Pediatric Heart Failure
    Butts, R.
    Nandi, D.
    Hong, B.
    Lorts, A.
    Spinner, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (04): : S479 - S479
  • [5] SGLT2 Inhibitors Who Should Prescribe Them for Patients With Heart Failure?
    Cheng, Richard K.
    Mooney, Deidre M.
    Chien, Christopher V.
    Shah, Kevin S.
    Vest, Amanda
    Jefferies, John L.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (10) : 1375 - 1377
  • [6] Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
    Kim, Yong Sook
    Ahn, Youngkeun
    KOREAN CIRCULATION JOURNAL, 2019, 49 (12) : 1196 - 1198
  • [7] Is It Time to Relitigate SGLT2 Inhibitor Dose for Heart Failure?
    Howlett, Jonathan G.
    CANADIAN JOURNAL OF CARDIOLOGY, 2023, 39 (05) : 662 - 664
  • [8] SGLT2 Inhibitor, an Agent for Diabetes, Heart, Kidney ... and Stroke
    Yang, Taeil
    Lee, Jooyeon
    Oh, Jaewon
    KOREAN CIRCULATION JOURNAL, 2024, 54 (09) : 562 - 564
  • [9] Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond
    Martens P.
    Mathieu C.
    Verbrugge F.H.
    Current Treatment Options in Cardiovascular Medicine, 2017, 19 (3)
  • [10] Dapagliflozin, an SGLT2 inhibitor, for diabetes
    Hanefeld, Markolf
    Forst, Thomas
    LANCET, 2010, 375 (9733): : 2196 - 2198
12345